Literature DB >> 1066171

Human acute myelomonocytic leukemia: serologic studies with simian antisera.

T Mohanakumar, D S Miller, R S Metzgar.   

Abstract

Simian antisera to human leukemia cells were able to distinguish antigens specific for lymphocytic types of leukemia from those expressed on certain myeloid leukemia cells. In this investigation, cells from acute myelomonocytic leukemia patients (AMML) were examined for their membrane-associated leukemia antigens. Simian antisera to both lymphocytic and myelogenous leukemia cells lysed cells from AMML donors. Monkey antisera to AMML cells, by direct microcytotoxicity testing, were cytotoxic for cells from all AMML patients, as well as for cells of certain patients with myeloid leukemia. Cells from patients with lymphatic leukemia were nonreactive. However, absorption studies indicated an antigen present on cells from patients with chronic lymphocytic leukemia which cross-reacted with AMML cell antigens. Sequential analyses of the serologic reactivity of cells from AMML patients undergoing chemotherapy corresponded with the clinical course of the patient, even though there was little correlation between the percentage of blast cells present and the per cent cytotoxicity with the antisera. At certain times a higher percentage of seropositive cells could be detected over that seen on morphological evaluation. The estimation of leukemic cells by serologic means could aid in the diagnosis and management of AMML patients during chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1066171

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  A 125I-protein A-binding assay detecting antibodies to cell surface antigens. Evidence for the presence of specific antibodies against leukemia-associated antigens in human leukemias.

Authors:  R Fäldt; J Ankerst
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Antigens expressed by human B lymphocytes and myeloid stem cells.

Authors:  M J Cline; R Billing
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.